Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Dec;74(6):911-9.
doi: 10.1111/j.1365-2125.2012.04278.x.

Gut hormones: the future of obesity treatment?

Anne K McGavigan  1 , Kevin G Murphy
Affiliations
Review

Gut hormones: the future of obesity treatment?

Anne K McGavigan et al. Br J Clin Pharmacol. 2012 Dec.

Abstract

Obesity is a major worldwide health problem. The treatment options are severely limited. The development of novel anti-obesity drugs is fraught with efficacy and safety issues. Consequently, several investigational anti-obesity drugs have failed to gain marketing approval in recent years. Anorectic gut hormones offer a potentially safe and viable option for the treatment of obesity. The prospective utility of gut hormones has improved drastically in recent years with the development of longer acting analogues. Additionally, specific combinations of gut hormones have been demonstrated to have additive anorectic effects. This article reviews the current stage of anti-obesity drugs in development, focusing on gut hormone-based therapies.

PubMed Disclaimer

References

    1. Aresu M, Chaudhury M, Diment E, Fuller E, Gordon-Dseagu V, Gunning N, Mindell J, Nicholson S, Ogunbadejo T, Robinson C, Roderick P, Roth M, Shelton N, Tabassum F, Wardle H. Health survey for England – 2009: trend tables. The NHS information centre for health and social care. 2010.
    1. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293:43–53. - PubMed
    1. Powell AG, Apovian CM, Aronne LJ. New drug targets for the treatment of obesity. Clin Pharmacol Ther. 2011;90:40–51. - PubMed
    1. Vivus Inc. Press Release. New long-term data on QNEXA® show significant and sustained weight loss of greater than 10% over two years. 2010. Available at http://files.shareholder.com/downloads/VVUS/1475992835x0x404069/76148ab7... (last accessed 12 April 2012)
    1. Vivus Inc. Press release. FDA Issues complete response letter to Vivus regarding new drug application for QNEXA®. 2010. Available at http://ir.vivus.com/releasedetail.cfm?ReleaseID=524576 (last accessed 12 April 2012)

MeSH terms

Substances